Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Cash from Investing Activities (2016 - 2025)

Regenxbio (RGNX) has 11 years of Cash from Investing Activities data on record, last reported at $37.5 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 6.79% year-over-year to $37.5 million; the TTM value through Dec 2025 reached -$15.9 million, down 115.34%, while the annual FY2025 figure was -$15.9 million, 115.34% down from the prior year.
  • Cash from Investing Activities reached $37.5 million in Q4 2025 per RGNX's latest filing, down from $42.3 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $63.1 million in Q1 2023 and bottomed at -$216.4 million in Q4 2021.
  • Average Cash from Investing Activities over 5 years is -$7.0 million, with a median of $30.3 million recorded in 2022.
  • Peak YoY movement for Cash from Investing Activities: surged 5208.05% in 2023, then tumbled 52301.49% in 2025.
  • A 5-year view of Cash from Investing Activities shows it stood at -$216.4 million in 2021, then surged by 112.34% to $26.7 million in 2022, then grew by 27.24% to $34.0 million in 2023, then grew by 18.54% to $40.3 million in 2024, then fell by 6.79% to $37.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were $37.5 million in Q4 2025, $42.3 million in Q3 2025, and -$140.4 million in Q2 2025.